EGFR and non-small cell lung carcinoma: Similarly, in non-small cell lung cancer, the overabundance of TRIP13 intensifies resistance to gefitinib through the manipulation of autophagy processes and the alteration of phosphorylation within the epidermal growth factor receptor (EGFR) signaling pathway [7].